UDCA, as an exogenous hydrophilic bile acid that replaces endogenous hydrophobic bile acids and obeticholic acid as FXR agonists, have been used to treat PBC (Gulamhusein and Hirschfield, 2020). This evidence concerns the gene NR1H4 and primary biliary cholangitis.